SK bioscience : Material Business Matters Related to Investment Decisions (Approval of change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17))

Material Business Matters Related to Investment Decisions

1. Title	Approval of change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17)
2. Details	1. Product name - NVX-CoV2373 (SARS-CoV-2 recombinant vaccine) 2. Target disease - Prevention of coronavirus infection-19 (COVID-19) caused by SARS-CoV-2 3. Date of application for product approval and approval agency - Application Date: April 7, 2022 - Approval Date: August 12, 2022 - Clinical trial approval institution: Ministry of Food and Drug Safety (MFDS) 4. Expected benefits - Recombinant SARS-CoV-2 antigen protein contained in this vaccine forms the antibodies against the SARS-CoV-2 virus inside the body, and exhibits an immune response when exposed to the SARS-CoV-2, enabling prevention against COVID-19. - It is expected that the vaccination rate will be increased and safety of all ages including adolescents will be maintained. 5. Future Plans - Scheduled to start vaccination for adolescents
3. Date of board resolution (decision date) or confirmation date	2022-08-12
- Attendance of outside directors	Present(No.)	-
Absent(No.)	-
- Attendance of auditors (members of Audit Committee who are not outside directors)	-
4. Other matters to be factored into investment decisions
- The above '3. Date of board resolution (decision date) or confirmation date' is the date of the approval.
※ Related disclosure	2022-04-11 Material Business Matters Related to Investment Decisions(Application for change of domestic product license for Novavax Corona 19 vaccine (addition of indications for adolescents aged 12 to 17))